Polypeptide conjugates of d-penicillamine and idarubicin for anticancer therapy

Journal of Controlled Release

Volumn 158, Issue 2, 2012, Pages 215-223

  Wadhwa, Saurabh ^a   Mumper, Russell J ^a,b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Anthracycline; Hydrazone; Oxidative stress; Thiol; Tumor

Indexed keywords

ANTHRACYCLINE; ANTI-CANCER THERAPIES; ATHYMIC; CANCER CELL LINES; CELL UPTAKE; DRUG-CONJUGATES; GLUTATHIONES; HYDRAZONE BONDS; HYDRAZONES; IN-VITRO; L-GLUTAMIC ACIDS; MEDIAN SURVIVAL; PHARMACOKINETIC STUDIES; RELEASE MEDIA; SUSTAINED RELEASE; THERAPEUTIC INDEX; THIOL; TUMOR GROWTH; TUMOR XENOGRAFTS;

AMINO ACIDS; CELL CULTURE; DRUG PRODUCTS; OXIDATIVE STRESS; TUMORS;

DRUG DOSAGE;

DISULFIDE; GLUTATHIONE; HYDRAZONE DERIVATIVE; IDARUBICIN; PENICILLAMINE; POLYGLUTAMIC ACID;

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; HUMANS; IDARUBICIN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PENICILLAMINE; PEPTIDES; POLYGLUTAMIC ACID; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858702315     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.10.027     Document Type: Article

References (63)

1. K.R. Martin, and J.C. Barrett Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity Hum. Exp. Toxicol. 21 2002 71 75 (Pubitemid 34591267)
2. M.P. Murphy How mitochondria produce reactive oxygen species Biochem. J. 417 2009 1 13
3. P. Cejas, E. Casado, C. Belda-Iniesta, J. De Castro, E. Espinosa, A. Redondo, M. Sereno, M.A. Garcia-Cabezas, J.A. Vara, A. Dominguez-Caceres, R. Perona, and M. Gonzalez-Baron Implications of oxidative stress and cell membrane lipid peroxidation in human cancer Cancer Causes Control 15 2004 707 719 (Pubitemid 39066212)
4. J. Chandra, A. Samali, and S. Orrenius Triggering and modulation of apoptosis by oxidative stress Free Radic. Biol. Med. 29 2000 323 333
5. A. Gupte, and R.J. Mumper Copper chelation by d-penicillamine generates reactive oxygen species that are cytotoxic to human leukemia and breast cancer cells Free Radic. Biol. Med. 43 2007 1271 1278 (Pubitemid 47429936)
6. P.A. Havre, S. O'Reilly, J.J. McCormick, and D.E. Brash Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine Cancer Res. 62 2002 1443 1449 (Pubitemid 34407805)
7. A. Gupte, S. Wadhwa, and R.J. Mumper Enhanced intracellular delivery of the reactive oxygen species (ROS)-generating copper chelator d-penicillamine via a novel gelatin-d-penicillamine conjugate Bioconjug. Chem. 19 2008 1382 1388 (Pubitemid 352032337)
8. D.A. Joyce, D.N. Wade, and B.R. Swanson The pharmacokinetics of albumin conjugates of d-penicillamine in rats Drug Metab. Dispos. 17 1989 208 211 (Pubitemid 19083607)
9. D.A. Joyce, R.O. Day, and B.R. Murphy The pharmacokinetics of albumin conjugates of d-penicillamine in humans Drug Metab. Dispos. 19 1991 309 311
10. E. Lodemann Transport of D- and l-penicillamine by mammalian cells Biochem. Biophys. Res. Commun. 102 1981 775 783 (Pubitemid 12109950)
11. S. Wadhwa, and R.J. Mumper Intracellular delivery of the reactive oxygen species generating agent d-penicillamine upon conjugation to poly-l-glutamic acid Mol. Pharm. 7 2010 854 862
12. P. Borchmann, K. Hubel, R. Schnell, and A. Engert Idarubicin: a brief overview on pharmacology and clinical use Int. J. Clin. Pharmacol. Ther. 35 1997 80 83 (Pubitemid 27081326)
13. D.A. Gewirtz A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem. Pharmacol. 57 1999 727 741 (Pubitemid 29094544)
14. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229 (Pubitemid 38720829)
15. J.R. Muindi, B.K. Sinha, L. Gianni, and C.E. Myers Hydroxyl radical production and DNA damage induced by anthracycline-iron complex FEBS Lett. 172 1984 226 230 (Pubitemid 14098852)
16. X. Xu, H.L. Persson, and D.R. Richardson Molecular pharmacology of the interaction of anthracyclines with iron Mol. Pharmacol. 68 2005 261 271 (Pubitemid 41058288)
17. K.D. Held, F.C. Sylvester, K.L. Hopcia, and J.E. Biaglow Role of Fenton chemistry in thiol-induced toxicity and apoptosis Radiat. Res. 145 1996 542 553 (Pubitemid 26127161)
18. H. Eliot, L. Gianni, and C. Myers Oxidative destruction of DNA by the adriamycin-iron complex Biochemistry 23 1984 928 936 (Pubitemid 14168072)
19. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360 (Pubitemid 37361705)
20. P.C. Rodrigues, U. Beyer, P. Schumacher, T. Roth, H.H. Fiebig, C. Unger, L. Messori, P. Orioli, D.H. Paper, R. Mulhaupt, and F. Kratz Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution Bioorg. Med. Chem. 7 1999 2517 2524 (Pubitemid 30122753)
21. K. Ulbrich, V. Subr, J. Strohalm, D. Plocova, M. Jelinkova, and B. Rihova Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation J. Control. Release 64 2000 63 79 (Pubitemid 30035308)
22. K. Ulbrich, T. Etrych, P. Chytil, M. Jelinkova, and B. Rihova HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity J. Control. Release 87 2003 33 47 (Pubitemid 36258386)
23. H. Maeda, L.W. Seymour, and Y. Miyamoto Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo Bioconjug. Chem. 3 1992 351 362
24. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
25. M.J. Vicent Polymer-drug conjugates as modulators of cellular apoptosis AAPS J. 9 2007 E200 E207 (Pubitemid 47007409)
26. T. Herzog, R.J. Barret, R. Edwards, and F.B. Oldham Phase II study of paclitaxel poliglumex (PPX)/carboplatin (C) for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma J. Clin. Oncol. 23 2005 458s-458s
27. M.J. Vicent, F. Greco, R.I. Nicholson, A. Paul, P.C. Griffiths, and R. Duncan Polymer therapeutics designed for a combination therapy of hormone-dependent cancer Angew. Chem. Int. Ed Engl. 44 2005 4061 4066 (Pubitemid 40886448)
28. S.S. Dharap, Y. Wang, P. Chandna, J.J. Khandare, B. Qiu, S. Gunaseelan, P.J. Sinko, S. Stein, A. Farmanfarmaian, and T. Minko Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide Proc. Natl. Acad. Sci. U. S. A. 102 2005 12962 12967 (Pubitemid 41279472)
29. B.K. Kishore, P. Lambricht, G. Laurent, P. Maldague, R. Wagner, and P.M. Tulkens Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-l-glutamic and poly-d-glutamic acids J. Pharmacol. Exp. Ther. 255 1990 875 885
30. X. Wen, E.F. Jackson, R.E. Price, E.E. Kim, Q. Wu, S. Wallace, C. Charnsangavej, J.G. Gelovani, and C. Li Synthesis and characterization of poly(l-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent Bioconjug. Chem. 15 2004 1408 1415 (Pubitemid 39552032)
31. C. Li Poly(l-glutamic acid) - anticancer drug conjugates Adv. Drug Deliv. Rev. 54 2002 695 713 (Pubitemid 35247523)
32. S.D. Chipman, F.B. Oldham, G. Pezzoni, and J.W. Singer Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate Int. J. Nanomedicine 1 2006 375 383
33. C.J. Langer, K.J. O'Byrne, M.A. Socinski, S.M. Mikhailov, K. Lesniewski-Kmak, M. Smakal, T.E. Ciuleanu, S.V. Orlov, M. Dediu, D. Heigener, A.J. Eisenfeld, L. Sandalic, F.B. Oldham, J.W. Singer, and H.J. Ross Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer J. Thorac. Oncol. 3 2008 623 630 (Pubitemid 351787307)
34. P. Sabbatini, C. Aghajanian, D. Dizon, S. Anderson, J. Dupont, J.V. Brown, W.A. Peters, A. Jacobs, A. Mehdi, S. Rivkin, A.J. Eisenfeld, and D. Spriggs Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma J. Clin. Oncol. 22 2004 4523 4531 (Pubitemid 41185119)
35. C. Gnaccarini, S. Peter, U. Scheffer, S. Vonhoff, S. Klussmann, and M.W. Gobel Site-specific cleavage of RNA by a metal-free artificial nuclease attached to antisense oligonucleotides J. Am. Chem. Soc. 128 2006 8063 8067 (Pubitemid 43945748)
36. S. Van, S.K. Das, X. Wang, Z. Feng, Y. Jin, Z. Hou, F. Chen, A. Pham, N. Jiang, S.B. Howell, and L. Yu Synthesis, characterization, and biological evaluation of poly(l-gamma-glutamyl-glutamine)-paclitaxel nanoconjugate Int. J. Nanomedicine 5 2010 825 837
37. M.H. Ullman-Cullere, and C.J. Foltz Body condition scoring: a rapid and accurate method for assessing health status in mice Lab. Anim. Sci. 49 1999 319 323 (Pubitemid 29284390)
38. K. Ulbrich, and V. Subr Polymeric anticancer drugs with pH-controlled activation Adv. Drug Deliv. Rev. 56 2004 1023 1050 (Pubitemid 38520207)
39. B. Arunachalam, U.T. Phan, H.J. Geuze, and P. Cresswell Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT) Proc. Natl. Acad. Sci. U. S. A. 97 2000 745 750 (Pubitemid 30070380)
40. W. Gao, R. Langer, and O.C. Farokhzad Poly(ethylene glycol) with observable shedding Angew. Chem. Int. Ed Engl. 49 2010 6567 6571
41. M.D. Partis, D.G. Griffiths, G.C. Roberts, and R.B. Beechey Cross-linking of protein by omega-maleimido alkanoyl N-hydroxysuccinimido esters J. Protein Chem. 2 1983 263 277 (Pubitemid 14200049)
42. F. Kratz, U. Beyer, P. Schumacher, M. Kruger, H. Zahn, T. Roth, H.H. Fiebig, and C. Unger Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates Bioorg. Med. Chem. Lett. 7 1997 617 622 (Pubitemid 27093079)
43. F. Kratz, A. Warnecke, K. Scheuermann, C. Stockmar, J. Schwab, P. Lazar, P. Druckes, N. Esser, J. Drevs, D. Rognan, C. Bissantz, C. Hinderling, G. Folkers, I. Fichtner, and C. Unger Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound J. Med. Chem. 45 2002 5523 5533 (Pubitemid 35424970)
44. M.R. Dreher, D. Raucher, N. Balu, O. Michael Colvin, S.M. Ludeman, and A. Chilkoti Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy J. Control. Release 91 2003 31 43 (Pubitemid 37303992)
45. J.A. MacKay, M. Chen, J.R. McDaniel, W. Liu, A.J. Simnick, and A. Chilkoti Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection Nat. Mater. 8 2009 993 999
46. C. Krejtschi, and K. Hauser Stability and folding dynamics of polyglutamic acid Eur. Biophys. J. 40 2011 673 685
47. R. Lumry, R. Legare, and W.G. Miller The dynamics of the helix-coil transition in poly-α, l-glutamic acid Biopolymers 2 1964 489 500
48. T. Etrych, P. Chytil, M. Jelinkova, B. Rihova, and K. Ulbrich Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity Macromol. Biosci. 2 2002 43 52 (Pubitemid 44790994)
49. A.J. D'Souza, and E.M. Topp Release from polymeric prodrugs: linkages and their degradation J. Pharm. Sci. 93 2004 1962 1979 (Pubitemid 39045479)
50. A. Nori, K.D. Jensen, M. Tijerina, P. Kopeckova, and J. Kopecek Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells Bioconjug. Chem. 14 2003 44 50 (Pubitemid 36169015)
51. L.M. Hollingshead, and D. Faulds Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer Drugs 42 1991 690 719 (Pubitemid 21920780)
52. R.S. Greenfield, T. Kaneko, A. Daues, M.A. Edson, K.A. Fitzgerald, L.J. Olech, J.A. Grattan, G.L. Spitalny, and G.R. Braslawsky Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker Cancer Res. 50 1990 6600 6607 (Pubitemid 20348786)
53. T. Minko, P. Kopeckova, and J. Kopecek Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line J. Control. Release 59 1999 133 148 (Pubitemid 29199920)
54. R. Bhatt, P. de Vries, J. Tulinsky, G. Bellamy, B. Baker, J.W. Singer, and P. Klein Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin J. Med. Chem. 46 2003 190 193 (Pubitemid 36043799)
55. N. Dos Santos, D. Waterhouse, D. Masin, P.G. Tardi, G. Karlsson, K. Edwards, and M.B. Bally Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity J. Control. Release 105 2005 89 105 (Pubitemid 40805478)
56. G.P. Zara, A. Bargoni, R. Cavalli, A. Fundaro, D. Vighetto, and M.R. Gasco Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats J. Pharm. Sci. 91 2002 1324 1333 (Pubitemid 34651194)
57. S.A. Shaffer, C. Baker-Lee, J. Kennedy, M.S. Lai, P. de Vries, K. Buhler, and J.W. Singer In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases Cancer Chemother. Pharmacol. 59 2007 537 548 (Pubitemid 46122332)
58. D. Chan-Lam, J.A. Copplestone, A. Prentice, R. Price, S. Johnson, and M. Phillips Idarubicin cardiotoxicity in acute myeloid leukaemia Lancet 340 1992 185 186
59. D. Platel, P. Pouna, S. Bonoron-Adele, and J. Robert Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model Anticancer Drugs 10 1999 671 676 (Pubitemid 29450209)
60. M.D. Sutherland, P. Thorkildson, S.D. Parks, and T.R. Kozel In vivo fate and distribution of poly-gamma-d-glutamic acid, the capsular antigen from Bacillus anthracis Infect. Immun. 76 2008 899 906 (Pubitemid 351428048)
61. P. Ma, X. Dong, C.L. Swadley, A. Gupte, M. Leggas, H.C. Ledebur, and R.J. Mumper Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia J. Biomed. Nanotechnol. 5 2009 151 161
62. Y. Boucher, J.M. Kirkwood, D. Opacic, M. Desantis, and R.K. Jain Interstitial hypertension in superficial metastatic melanomas in humans Cancer Res. 51 1991 6691 6694
63. R.K. Jain Transport of molecules in the tumor interstitium: a review Cancer Res. 47 1987 3039 3051 (Pubitemid 17082621)